Navigation Links
Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO

BERKELEY HEIGHTS, N.J., June 04, 2007 /PRNewswire-FirstCall/ -- Genta Incorporated announced the presentation of results from a Phase 2 clinical trial of its marketed product, Ganite(R) (gallium nitrate injection), plus rituximab (Rituxan(R); Genentech/IDEC) and dexamethasone in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL). The data were presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL.

Previously published studies have indicated that high doses of gallium nitrate used alone or in combination with chemotherapy showed preliminary evidence of clinical activity in patients with Hodgkin's disease and non- Hodgkin's lymphoma. Based on these data, investigators at Loyola University Medical Center sought to incorporate gallium nitrate into a minimally myelosuppressive "salvage" regimen (called "GaRD") that was designed to treat patients who had failed multiple types of standard therapy.

In the GaRD trial, gallium nitrate was administered in combination with rituximab and dexamethasone. Twenty-two patients with NHL were entered into this study, most of whom had been refractory to multiple salvage therapies. All patients had failed prior treatment with rituximab, including 18 of 22 who received rituximab in their last regimen. Overall, 41% of patients achieved a major objective response, including 8 (36%) with complete or unconfirmed complete responses and 1 (5%) with a partial response. Two of the major responders had previously failed a stem cell transplant; both patients remain in sustained remission 14+ and 18+ months after their last relapse. Six other patients achieved stable disease. Five patients subsequently underwent a stem cell transplant. Of all 22 patients treated with the GaRD regimen, 46% are alive at a median followup of 17+ months, and 7 are currently without evidence of disease.

No non-hematologic Grade 4 advers
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:7/28/2015)... July 28, 2015 ... report with market overview, trends, DRO analysis, ... analysis, recent developments, competitive scenario and top ... Insight: Human Insulin Market Development and Demand ... http://photos.prnewswire.com/prnh/20150727/756778) Explore more about Global ...
(Date:7/28/2015)... , July 28, 2015  Cepheid (Nasdaq: ... flexible and portable clinical molecular diagnostic system designed ... Care market.  At just 9 inches tall, and ... run the same high quality PCR-based Xpert® cartridges ... highly accurate clinical molecular diagnostic tests to be ...
(Date:7/28/2015)... , July 28, 2015 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" ... announce that it has received final approval for its common ... Stock Exchange (the "TSX"). The Company,s common shares will commence ... 2015 under the trading symbol ,EPI,.  Concurrently, ESSA,s common shares ... About ESSA Pharma Inc. ESSA Pharma is ...
Breaking Medicine Technology:Global Human Insulin Market (Size of $24 billion in 2014) to Witness 13% CAGR During 2015 - 2020 2Global Human Insulin Market (Size of $24 billion in 2014) to Witness 13% CAGR During 2015 - 2020 3Global Human Insulin Market (Size of $24 billion in 2014) to Witness 13% CAGR During 2015 - 2020 4Global Human Insulin Market (Size of $24 billion in 2014) to Witness 13% CAGR During 2015 - 2020 5World's First "Go-Anywhere" Molecular Diagnostic System Unveiled at AACC 2World's First "Go-Anywhere" Molecular Diagnostic System Unveiled at AACC 3World's First "Go-Anywhere" Molecular Diagnostic System Unveiled at AACC 4ESSA Pharma Inc. to Commence Trading on the Toronto Stock Exchange 2ESSA Pharma Inc. to Commence Trading on the Toronto Stock Exchange 3
... (NASDAQ: MASI ) today announced that in line ... Cost of Care by Taking Noninvasive Monitoring to New Sites ... (SpHb®) will further the company,s stated mission,  Masimo is introducing ... ransfusion R elated C ost R eduction ...
... JAZZ ) today announced that the company will host ... 2011 at 4:30 p.m. EST/9:30 p.m. GMT. During the call, ... quarter and full year 2011 financial results. The ... Investors section of the Jazz Pharmaceuticals, website at www.jazzpharmaceuticals.com ...
Cached Medicine Technology:Masimo Announces "Better Care" Program - A Hospital Risk-Share Program for Blood Transfusion Related Cost Reduction with SpHb®, and $30 SpHb Sensor Price 2Masimo Announces "Better Care" Program - A Hospital Risk-Share Program for Blood Transfusion Related Cost Reduction with SpHb®, and $30 SpHb Sensor Price 3Masimo Announces "Better Care" Program - A Hospital Risk-Share Program for Blood Transfusion Related Cost Reduction with SpHb®, and $30 SpHb Sensor Price 4Masimo Announces "Better Care" Program - A Hospital Risk-Share Program for Blood Transfusion Related Cost Reduction with SpHb®, and $30 SpHb Sensor Price 5Masimo Announces "Better Care" Program - A Hospital Risk-Share Program for Blood Transfusion Related Cost Reduction with SpHb®, and $30 SpHb Sensor Price 6Masimo Announces "Better Care" Program - A Hospital Risk-Share Program for Blood Transfusion Related Cost Reduction with SpHb®, and $30 SpHb Sensor Price 7
(Date:7/28/2015)... , ... July 28, 2015 , ... Women fear developing ... reason is that cancer, heart attack, and stroke are treatable, but there is little ... can do is to take part in a clinical trial, reports the July 2015 ...
(Date:7/28/2015)... CA (PRWEB) , ... July 28, 2015 , ... ... of Acute Coronary Syndromes (ACS-Heart Attack, Sudden Death, or Angina), many of whom ... cardiology is the identification of individuals with active yet undetected sub-clinical disease, who ...
(Date:7/28/2015)... ... July 28, 2015 , ... ... for identifying Top Doctors, has based its selection process on the foundation of ... in their medical specialties, in any area of medicine and in any part ...
(Date:7/28/2015)... ... 2015 , ... One of the most common running related ... plantar fasciitis . Zensah, the Miami-based compression brand, offers a product that can ... the Zensah Ankle Support’s primary benefits include helping support the ankle, reduce swelling, ...
(Date:7/28/2015)... ... July 28, 2015 , ... Nurses across all settings ... up to 57 million Americans may need mental health services (SAMHSA, 2013) and the ... Psychiatric-mental health RNs are one of the largest workforces who provide care to ...
Breaking Medicine News(10 mins):Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 2Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 3Health News:Utility of a novel coronary artery disease biomarker algorithm in modifying physician adherence to guideline therapy presented at 20th World Congress on Heart Disease 2Health News:Fort Myers Plastic Surgeon Recognized as One of the America’s “Top Doctors®” by Prestigious Castle Connolly Medical Ltd. for 5 Years in a Row 2Health News:Fort Myers Plastic Surgeon Recognized as One of the America’s “Top Doctors®” by Prestigious Castle Connolly Medical Ltd. for 5 Years in a Row 3Health News:Zensah Releases Compression Sleeve To Relieve Ankle Pain and Plantar Fasciitis 2Health News:American Psychiatric Nurses Association Transitions in Practice Certificate Program to Improve Mental Health Care Through Continuing Nursing Education 2Health News:American Psychiatric Nurses Association Transitions in Practice Certificate Program to Improve Mental Health Care Through Continuing Nursing Education 3Health News:American Psychiatric Nurses Association Transitions in Practice Certificate Program to Improve Mental Health Care Through Continuing Nursing Education 4
... Taiwan researchers said Thursday they have successfully tested 10 ... while prolonging patients' survival time with limited side ... led by Dr. Wong Chi-huey, president of Taiwan's highest ... in the structure and function of sugars. ...
... all financial aid to Amnesty International and called on ... accusing it of promoting abortion. "No more Catholic ... said a statement from the Vatican's Pontifical Council for ... Renato Martino, said the "suspension of all financing of ...
... concept catching up fast in the West. ,With the ... phones with hundreds of names and numbers stored in its ... these numbers belong to the near and dear. ,In ... had a heart attack and the physicians attending on the injured ...
... for Allergy & Immunology (LIAI) made an important finding, ... for treating autoimmune and inflammatory diseases such as ... studies, conducted in laboratory mice, demonstrated the role of ... broken down in the body, in regulating inflammation. ...
... Melbourne's Yarra River, posing serious threat to wildlife in the ... with the water until the slick - from the Chandler ... ,The Environment Protection Agency (EPA) is investigating the source ... but was not discovered until Tuesday by a kayaker using ...
... University of Illinois at Chicago and Cornell University are ... patients who suffer from Neurodegenerative diseases or stroke . ... events take place that lead to the death of ... called histone deacetylases can modulate gene expression, and in ...
Cached Medicine News:Health News:Taiwan Researchers Claim Cancer Therapy Alternative 2Health News:Catholics Should Halt Amnesty Support Over Abortion Issue: Vatican 2Health News:Look Out for ICE in Emergency Situations 2Health News:New Therapeutic Approach for Autoimmune and Inflammatory Diseases 2Health News:Australia Battles Oil Slick on Yarra River 2Health News:Researchers Developing New Therapy to Re-activate Silenced Genes 2
Immuno-turbidimetric assay for Free Protein Sby STA© Analyzers. Suspension of microparticles coated with monoclonal antibodies to Free Protein S....
Colorimetric Assay of Unfractionated and Low Molecular Weight Heparins by STA© Analyzers. Lyophilized, patent-pending chromogenic substate, CBS 52.44 of ~4.2 moles/vial and bovine factor Xa ~1.1...
Substrate Plasma for Factor VII Assay by STA© Analyzers. Freeze-dried human plasma from which factor VII has been removed by selective immuno-adsorption....
Substrate Plasma for Factor IX Assay by STA© Analyzers. Freeze-dried human plasma from which factor IX has been removed by selective immuno-adsorption....
Medicine Products: